(P14) Chapter 1: The Secrets to a Happy Lab: "One Interface in Many Chromatography Data Systems (CDSs) " The user-centric approach shown in Figures 5 and 6 has been implemented within Agilent’s RC.NET interface and Instrument Control Framework, enabling the same user experience and training approaches for using Agilent LCs within a non-Agilent data system as with a data system in the OpenLab CDS suite. When an instrument is straightforward to use, experienced chromatographers can focus their talents on high-value (and more interesting) tasks. “The Agilent 1290 Infinity II is extremely useful because even nonanalytical researchers can easily perform measurement tasks." - Kazuaki Kanai, PhD, President & CEO of JITSUBO.
(P24) Chapter 2: One Instrument, Many Methods: "Replace UHPLCs from Other Vendors" The ability of a single instrument to run a wide range of applications, including HPLC and UHPLC in a single flow path, is a significant improvement over the prior practice of needing to dedicate specific instruments to UHPLC. ・Figure 11. The Agilent 1290 Infinity II LC with ISET (in blue) delivers similar retention times and chromatographic resolution as the Waters Acquity H-Class when enabling ISET (in red). “By using ISET, the retention time and separation pattern obtained under the analysis conditions developed by other companies' LC will be assured. It can be reproduced, enabling technology transfer without changing complex impurity profiles. It is a very important function for us." - Kazuaki Kanai, PhD, President & CEO of JITSUBO. 0778山師さん@トレード中2020/01/24(金) 19:24:04.14ID:/SN/cFji0 サンバイオPTS爆上げ そーせいPTS大暴落ww 本物と偽物の違いを見せつける 0779山師さん@トレード中2020/01/24(金) 19:25:30.91ID:4iRA4IZl0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 ・・・ ※SOSEIの成長相場の動向:再びの上昇相場は順調に推移(2018/12/25:最安値748※、2019/1/4:安値_780、2019/8/5:最高値:2794)。笑。業績相場への動意待ち。笑。 2018/12/28 (終値_799) 25日線_948.64(-15.77%) ・(12/25最安値_748) ※12/1:SoseiHeptares本格始動[再びの拾い場※][強気相場からの時間軸調整が終了] 2019/_1/_4 (終値_864) 25日線_940.80( -8.16%) ・(_1/_4安値_780) ※1/1:田村CEO復帰※1/7:AZD4635第U相[1/8ストップ高:終値1078] [上昇トレンドへ転換] 2019/_2/_1 (終値1021) 25日線1051.28( -2.88%) ・(_1/30安値_985) ※空売り価格規制トリガー抵触(1/21安値1164, 1/30安値985)※(1/21:高値更新:1360) 2019/_3/_1 (終値1250) 25日線1133.28(+10.83%) ・(_2/_4安値1021) ※2/14:決算 ※2/22:IR説明会(阿倍野)「次なる成長ステージに向けた成長戦略」 2019/_4/_5 (終値1593) 25日線1331.60(+19.63%) ・(_3/11安値1105) ※3/16:中国上市 ※(3/20:高値更新:ストップ高:1526) ※3/29:IR説明会(名古屋・大阪) 2019/_5/10 (終値1486) 25日線1494.08( -0.54%) ・(_4/22安値1372) ※空売り価格規制トリガー抵触(4/11安値1400) ※(4/9:高値更新:1717)※(5/15:高値更新:1743) 2019/_6/_7 (終値2014) 25日線1800.28(+11.87%) ・(_5/13安値1429) ※5/14:Pfizer進捗;第1四半期決算 ※5/24:QVM149申請 ※高値更新:(5/22:1834)(5/23:2149)(5/28:2296) 2019/_7/_5 (終値2338) 25日線2172.52( +7.62%) ・(_6/12安値1969) ※6/10:Pfizer進捗※6/18:IR説明会(仙台) ※高値更新:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482) 2019/_8/_2 (終値2544) 25日線2448.12( +3.92%) ・(_7/_9安値2216) ※7/16:Genentech提携※(7/16ストップ高:高値更新:2773) ※7/18:APP13007進捗 2019/_9/_6 (終値2335) 25日線2463.68( -5.22%) ・(_8/30安値2179) ※8/5:武田薬品提携 ※8/5:高値更新:2794) ※8/13:第2四半期決算 [踊り場にて動意待ち] 2019/10/_4 (終値2438) 25日線2342.44(+4.08%) ・(_9/17安値2088) ※9/12:インベスターR&D Day ※9/28:MTL-CEBPA単剤第T相最終結果※9/30:QVM149第V相IRIDIUM結果 2019/11/_1 (終値2570) 25日線2385.96(+7.71%) ・(10/11安値2130) ※10/9:Genentech進捗 2019/12/_6 (終値2317) 25日線2346.72( -1.27%) ・(11/15安値2185) ※11/12:第3四半期決算※空売り価格規制トリガー(11/13)※11/28:中国NRDL収載※12/6:IR説明会(広島) 2019/12/30 (終値2171) 25日線2241.00( -3.12%) ・(12/16安値2137) ※12/23:Pfizer第T相開始※12/24:Pfizer進捗(三番目) ※2019年大納会 0780山師さん@トレード中2020/01/24(金) 19:25:46.65ID:4iRA4IZl0 2020/_1/_6 (終値2117) 5日線2211.40( -4.27%) 25日線2235.12(-5.28%) 75日線2322.30( -8.84%) 200日線2115.53(+0.01%) (安値2110) ※2020年大発会始値2150 2020/_1/_7 (終値2117) 5日線2189.20( -3.30%) 25日線2229.88(-5.06%) 75日線2319.32( -8.72%) 200日線2120.30( -0.16%) (安値2115) ※1/7:MiNA Collaboration with AstraZeneca. 2020/_1/_8 (終値2012) 5日線2137.20( -5.86%) 25日線2219.48(-9.35%) 75日線2316.09(-13.13%) 200日線2124.78( -5.31%) (安値1977) 2020/_1/_9 (終値2047) 5日線2092.80( -2.19%) 25日線2209.80(-7.37%) 75日線2313.70(-11.53%) 200日線2129.23( -3.86%) (安値2030) 2020/_1/10 (終値2115) 5日線2081.60(+1.60%) 25日線2203.64(-4.02%) 75日線2312.40( -8.54%) 200日線2133.80( -0.88%) (安値2038) ・(1/8安値1977) 2020/_1/14 (終値2104) 5日線2079.00(+1.20%) 25日線2195.48(-4.17%) 75日線2310.85( -8.95%) 200日線2138.24( -1.60%) (安値2092) ※1/14:Orexia&Inexia進捗 2020/_1/15 (終値2139) 5日線2083.40(+2.67%) 25日線2188.36(-2.26%) 75日線2309.37( -7.38%) 200日線2142.99( -0.19%) (安値2108) ※1/15:J.P. Morgan Healthcare Conference 2020/_1/16 (終値2150) 5日線2111.00(+1.85%) 25日線2185.00(-1.60%) 75日線2306.90( -6.80%) 200日線2147.81(+0.10%) (安値2115) 2020/_1/17 (終値2148) 5日線2131.20(+0.79%) 25日線2178.24(-1.39%) 75日線2302.36( -6.70%) 200日線2152.48( -0.21%) (安値2135) ・(1/14安値2092) 2020/_1/20 (終値2139) 5日線2136.00(+0.14%) 25日線2172.88(-1.56%) 75日線2297.89( -6.91%) 200日線2157.04( -0.84%) (安値2123) 2020/_1/21 (終値2134) 5日線2142.00( -0.37%) 25日線2168.28(-1.58%) 75日線2293.08( -6.94%) 200日線2160.61( -1.23%) (安値2121) 2020/_1/22 (終値2140) 5日線2142.20( -0.10%) 25日線2163.20(-1.07%) 75日線2288.82( -6.50%) 200日線2164.53( -1.13%) (安値2131) ※25日・200日線デッドクロス(1/22) 2020/_1/23 (終値2129) 5日線2138.00( -0.42%) 25日線2158.20(-1.35%) 75日線2284.90( -6.82%) 200日線2168.21( -1.81%) (安値2125) 2020/_1/24 (終値2106) 5日線2129.60( -1.11%) 25日線2154.24(-2.24%) 75日線2280.57( -7.65%) 200日線2171.81( -3.03%) (安値2061) ・(1/24安値2061) 0781山師さん@トレード中2020/01/24(金) 19:26:06.04ID:4iRA4IZl0 更なる成長の黎明期にて、前回の強気相場からの時間軸での調整が終り、再びの拾い場(底値)からの水準訂正は、3倍圏ステージにて順調に推移。笑。踊り場にて動意待ち。笑。 新生SoseiHeptares、次なる成長ステージに向けた成長戦略も順調に進展。笑。着実な拡充と共に、経営戦略の転換による黒字定着化。笑。更なる成長が楽しみですね。笑。 更なる再成長期、業績相場待ち。次なる成長ステージが楽しみですね。笑。今回(再び)の上昇相場も面白くなり、悪地合いにて新年相場が開始。笑。200日線調整中。笑。 0782山師さん@トレード中2020/01/24(金) 19:31:04.17ID:4iRA4IZl0 ※フィスコ:マザーズ先物概況:続落、主力級銘柄はそろって軟調。(1/24 15:38) 24日のマザーズ先物は前日比8.0pt安の861.0ptとなった。なお、高値872.0pt、安値は855.0pt、取引高は1551枚。 本日のマザーズ先物は、新型肺炎の感染拡大に対する警戒感から市場全体の上値が重いなか、時価総額上位銘柄群が下押しする形で大きく続落となった。 前日の米国市場では、新型コロナウィルスの感染拡大を巡っての懸念が強まり売りが先行。 ただ、世界保健機関(WHO)が非常事態宣言を見送ったことから引けにかけては下げ幅を縮小した。 こうした外部環境が良好とはいえない中、個別に材料のあったところへの物色は見られたものの、主力級の時価総額上位銘柄については大きく売り込まれるところが多かった。 スマホ決済サービスの統合に向けて、Origamiを買収すると発表したメルカリが3%超下げたこともマザーズ先物の重しとなった。 指数寄与度の高いところでは、メルカリ、Sansan、ラクス、サンバイオ、そーせいなどが大きく下落した。 0783山師さん@トレード中2020/01/24(金) 19:48:50.39ID:lbo1LqVh0 M1開発中止の思惑により信用買残777万の ぶん投げ祭りがおんどれらを襲う 0784山師さん@トレード中2020/01/24(金) 20:23:55.83ID:yMMe1p4G0 分投げカモン 下で待ってるで〜〜 0785山師さん@トレード中2020/01/24(金) 20:56:17.59ID:iMuTSwxXM それ絶好の買い場やん 0786山師さん@トレード中2020/01/24(金) 21:03:35.54ID:4iRA4IZl0 ※MRC LMB Twitter 1時間前:(1/24) ・Top cryo-EM machines cost about $7 million. "They are Cadillacs. But science would benefit from something less posh. Henderson says. “We need a people’s cryo-EM for maybe 10 times less: a Volkswagen Beetle.”
※Science: "‘We need a people’s cryo-EM.’ Scientists hope to bring revolutionary microscope to the masses". (1/23 Posted) The Laboratory for Molecular Biology (LMB), clad in glass the color of sea ice, rises like a futuristic factory above the rapeseed fields of Cambridge, U.K. It is the crown jewel of the U.K. Medical Research Council, a storied government lab that has garnered more than a dozen Nobel Prizes. One of the first came in 1962 after LMB researchers, having pioneered x-ray crystallography, used the technique to decipher the first atomic structures for proteins - those of myoglobin and hemoglobin, which carry oxygen in muscle tissue and blood. X-ray crystallography has dominated structural biology ever since, but it has an Achilles’ heel: Some proteins just can’t be coaxed to form crystals, which scatter x-rays to reveal structure. One of LMB’s most recent Nobel laureates is Richard Henderson, an unassuming Scotsman who slouches in his office chair in socks and sandals, surrounded by mountains of paperwork. In 2017, Henderson won a share of the chemistry prize for his work in developing detectors for cryo–electron microscopy (cryo-EM). The technique, also pioneered at LMB, is the brash upstart in structural biology, challenging crystallography in resolution and surpassing it in purview: It opens up far more proteins to inspection and captures many more of their natural configurations. Cryo-EM dodges the problem of crystallization with a flash-freezing process that fixes proteins in thin films of glassy ice. Then, an electron microscope takes thousands of 2D snapshots of the proteins caught in random orientations. A computer stitches them together to reveal the 3D structure, so important in understanding how a protein works - and how a drugmaker might target it. 0787山師さん@トレード中2020/01/24(金) 21:03:59.65ID:4iRA4IZl0 But cryo-EM has a big problem of its own: long waits to use extraordinarily expensive microscopes. Moreover, tricky sample preparation means that even when researchers get access, much of their time ends up wasted. “There’s this dirty little secret of the field,” says LMB physicist Chris Russo. “It’s almost as hard as making a crystal. There’s a lot of trial and error in it.” Some researchers are aiming to fix those problems with automation: robots that can make icy protein samples more reliably and with less waste. Other scientists are developing materials that protect protein molecules during freezing. Still others are working on software that could gather data more efficiently. But Henderson sees those efforts as mere Band-Aids. For him, what holds back the technique is the forbidding cost of a microscope. Henderson, Russo, and a small group of confederates are trying to make cryo-EM affordable. A top machine costs about $7 million. Preparing a room and installing a microscope can cost just as much. Then come the operational costs - a torrent of electricity, dedicated troubleshooting staff - that can rise to $10,000 per day. Roughly 130 Krios machines - the microscopes widely considered the best - have been sold by Thermo Fisher Scientific and installed around the world. LMB has the luxury of three for a relatively small staff, and yet even its researchers must wait a month or more to get time. 0788山師さん@トレード中2020/01/24(金) 21:04:22.25ID:4iRA4IZl0 Most structural biologists have no access at all. “The wait can be from 3 months to infinity,” says Bridget Carragher, codirector of the Simons Electron Microscopy Center in New York City, a mecca for cryo-EM. “It’s becoming the haves and the have-nots.” No one complains about the quality of the Krios machines, which take months to assemble by hand from thousands of parts in a Dutch factory. They are Cadillacs. But science would benefit from something less posh, Henderson says. “We need a people’s cryo-EM for maybe 10 times less: a Volkswagen Beetle.” For decades, microscopists have opted for machines that run at high energies and require expensive parts and precautions. After revisiting the basic physics, Henderson, Russo, and colleagues showed that a cheaper, lower-energy microscope can take pictures that are just as good, if not better. Now, Henderson hopes to persuade manufacturers to make his cut-rate machine. At less than $1 million, it should put cryo-EM within reach of thousands of labs. Doing so would democratize the field, he says, and accelerate the discovery of protein structures. At the very least, Carragher says, researchers could use a cheap machine to screen out bad samples, preventing wasted time on a Krios. “People need to learn the trade and try things out,” she says. “They shouldn’t be doing it on the glamour machine.” 0789山師さん@トレード中2020/01/24(金) 21:04:46.99ID:4iRA4IZl0 ・・・ Henderson set about finding smaller companies to take up the 100-keV mantle. He persuaded a U.K. company, York Probe Sources, to build a cheap field emission gun. “I started from a clean slate and designed it for 100 kilovolts,” says founder and electronics engineer Mohamed El Gomati. Henderson also enlisted the help of Swiss company Dectris, which says it can build detectors for less than £150,000. Sacha De Carlo, Dectris’s EM business development manager, expects the campaign by Henderson and colleagues will create demand for 100-keV detectors. “He’s extremely influential,” De Carlo says. And next month, JEOL will deliver to LMB the first of three cheap 100-keV microscopes - a basic model to which Henderson plans to add the field emission gun and detector. If he can wow fellow scientists with good results - and show that the price tag is well under $1 million - he’s confident that Thermo Fisher will snap to attention. “Either through shame or blackmail or bribery, we’ll get them to do it in the end,” Henderson jokes. Henderson already knows where he will put 100-keV machines. At LMB, he has been given space in a room formerly devoted to x-ray crystallography - a metaphor not lost on him. The small cryo-EM machines will fit easily in the room, with no need for renovations. One of the in-house x-ray sources has already been cleared away. A few technicians work on a declining library of crystals while Henderson squints to visualize the tools he’s trying to muscle into existence. “X-rays are on their way out, really,” he says. Cryo-EM - cheap cryo-EM - is on its way in. 0790山師さん@トレード中2020/01/24(金) 21:10:08.39ID:4iRA4IZl0 ※MRC LMB Twitter 1時間前:(1/24) ・Science Mmagazine's story profiles the longstanding work of "Richard Henderson, Christopher J Russo, and a small group of confederates who are trying to make cryo-EM affordable." All the you need to know about the science behind it in this story: 0791山師さん@トレード中2020/01/24(金) 21:38:06.27ID:fPh5Zf7w0 M1キタ━━(*^_^*)━━!! 0792山師さん@トレード中2020/01/24(金) 21:45:46.68ID:xeCFEXi50 ついにきたのか? 0793山師さん@トレード中2020/01/24(金) 22:18:33.60ID:TlPDrznsd>>791 おめぇぶっ殺すぞ 0794山師さん@トレード中2020/01/25(土) 06:00:14.26ID:HvHXLweh0 Event up: (1/24up)